| The biomedical use of silk: past, present, future C Holland, K Numata, J Rnjak‐Kovacina, FP Seib Advanced healthcare materials 8 (1), 1800465, 2019 | 653 | 2019 |
| Functional immobilization of signaling proteins enables control of stem cell fate K Alberti, RE Davey, K Onishi, S George, K Salchert, FP Seib, ... Nature methods 5 (7), 645-650, 2008 | 250 | 2008 |
| Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments MC Prewitz, FP Seib, M Von Bonin, J Friedrichs, A Stißel, C Niehage, ... Nature methods 10 (8), 788-794, 2013 | 242 | 2013 |
| pH‐dependent anticancer drug release from silk nanoparticles FP Seib, GT Jones, J Rnjak‐Kovacina, Y Lin, DL Kaplan Advanced healthcare materials 2 (12), 1606-1611, 2013 | 237 | 2013 |
| Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells FP Seib, AT Jones, R Duncan Journal of controlled release 117 (3), 291-300, 2007 | 236 | 2007 |
| Self‐assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer FP Seib, EM Pritchard, DL Kaplan Advanced functional materials 23 (1), 58-65, 2013 | 157 | 2013 |
| The growth and differentiation of mesenchymal stem and progenitor cells cultured on aligned collagen matrices B Lanfer, FP Seib, U Freudenberg, D Stamov, T Bley, M Bornhäuser, ... Biomaterials 30 (30), 5950-5958, 2009 | 154 | 2009 |
| Multifunctional silk–heparin biomaterials for vascular tissue engineering applications FP Seib, M Herklotz, KA Burke, MF Maitz, C Werner, DL Kaplan Biomaterials 35 (1), 83-91, 2014 | 131 | 2014 |
| PEGylated silk nanoparticles for anticancer drug delivery T Wongpinyochit, P Uhlmann, AJ Urquhart, FP Seib Biomacromolecules 16 (11), 3712-3722, 2015 | 123 | 2015 |
| Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer FP Seib, DL Kaplan Biomaterials 33 (33), 8442-8450, 2012 | 118 | 2012 |
| Matrix elasticity regulates the secretory profile of human bone marrow-derived multipotent mesenchymal stromal cells (MSCs) FP Seib, M Prewitz, C Werner, M Bornhäuser Biochemical and biophysical research communications 389 (4), 663-667, 2009 | 105 | 2009 |
| Degradation behavior of silk nanoparticles—enzyme responsiveness T Wongpinyochit, BF Johnston, FP Seib ACS Biomaterials Science & Engineering 4 (3), 942-951, 2018 | 85 | 2018 |
| Biocompatibility assessment of silk nanoparticles: hemocompatibility and internalization by human blood cells MF Maitz, C Sperling, T Wongpinyochit, M Herklotz, C Werner, FP Seib Nanomedicine: Nanotechnology, Biology and Medicine 13 (8), 2633-2642, 2017 | 83 | 2017 |
| Impact of processing parameters on the haemocompatibility of Bombyx mori silk films FP Seib, MF Maitz, X Hu, C Werner, DL Kaplan Biomaterials 33 (4), 1017-1023, 2012 | 82 | 2012 |
| Tissue engineering a surrogate niche for metastatic cancer cells FP Seib, JE Berry, Y Shiozawa, RS Taichman, DL Kaplan Biomaterials 51, 313-319, 2015 | 75 | 2015 |
| Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model B Chiu, J Coburn, M Pilichowska, C Holcroft, FP Seib, A Charest, ... British journal of cancer 111 (4), 708-715, 2014 | 70 | 2014 |
| Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ MR Reagan, FP Seib, DW McMillin, EK Sage, CS Mitsiades, SM Janes, ... Journal of breast cancer 15 (3), 273-282, 2012 | 64 | 2012 |
| Endogenous bone morphogenetic proteins in human bone marrow-derived multipotent mesenchymal stromal cells FP Seib, M Franke, D Jing, C Werner, M Bornhäuser European journal of cell biology 88 (5), 257-271, 2009 | 62 | 2009 |
| Metabolic Reprogramming of Macrophages Exposed to Silk, Poly(lactic‐co‐glycolic acid), and Silica Nanoparticles R Saborano, T Wongpinyochit, JD Totten, BF Johnston, FP Seib, IF Duarte Advanced Healthcare Materials 6 (14), 1601240, 2017 | 60 | 2017 |
| Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation B16F10 cells and … F Philipp Seib, AT Jones, R Duncan Journal of drug targeting 14 (6), 375-390, 2006 | 58 | 2006 |
